Miriam Hobbs

4.1k total citations
26 papers, 225 citations indexed

About

Miriam Hobbs is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Miriam Hobbs has authored 26 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 14 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Miriam Hobbs's work include Multiple Myeloma Research and Treatments (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers) and Cancer Treatment and Pharmacology (6 papers). Miriam Hobbs is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers) and Cancer Treatment and Pharmacology (6 papers). Miriam Hobbs collaborates with scholars based in United States, Australia and Canada. Miriam Hobbs's co-authors include Prashant Kapoor, S. Vincent Rajkumar, Shaji Kumar, Nelson Leung, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, David Dingli and Yi L. Hwa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Mayo Clinic Proceedings.

In The Last Decade

Miriam Hobbs

23 papers receiving 220 citations

Peers

Miriam Hobbs

HEMAT

ONCOL

GENET

RHEUM

Irini Xilouri Greece

Philip R. Greipp United States

F. W. Cremer Germany

Giulia Marzocchi Italy

Fernando Escalante Spain

Xiaoqi Qin China

Reinhard Ruckser Austria

Carlos Hader United States

Chang‐Liang Lai Taiwan

Cecilia Arana Yi United States

Irini Xilouri Greece

Miriam Hobbs

208 ×1.5

HEMAT

238 ×1.8

123 ×1.5

ONCOL

119 ×1.6

GENET

26 ×1.1

RHEUM

Citations per year, relative to Miriam Hobbs Miriam Hobbs (= 1×) peers Irini Xilouri

Countries citing papers authored by Miriam Hobbs

Since Specialization

Citations

This map shows the geographic impact of Miriam Hobbs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miriam Hobbs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miriam Hobbs more than expected).

Fields of papers citing papers by Miriam Hobbs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miriam Hobbs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miriam Hobbs. The network helps show where Miriam Hobbs may publish in the future.

Co-authorship network of co-authors of Miriam Hobbs

This figure shows the co-authorship network connecting the top 25 collaborators of Miriam Hobbs. A scholar is included among the top collaborators of Miriam Hobbs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miriam Hobbs. Miriam Hobbs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cook, Joselle, Rahma Warsame, Francis K. Buadi, et al.. (2025). Interleukin-6 is a highly prognostic biomarker for POEMS syndrome. Leukemia. 39(9). 2281–2284.

Charalampous, Charalampos, Prashant Kapoor, Moritz Binder, et al.. (2023). Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.. Journal of Clinical Oncology. 41(16_suppl). 8051–8051. 3 indexed citations

Ho, Matthew, Saurabh Zanwar, Prashant Kapoor, et al.. (2021). The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal. 11(9). 158–158. 6 indexed citations

Sidiqi, M Hasib, Abdullah S. Al Saleh, Shaji Kumar, et al.. (2021). Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology. 96(9). 1131–1136. 24 indexed citations

Muchtar, Eli, Angela Dispenzieri, Shaji Kumar, et al.. (2021). Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy. 27(7). 589.e1–589.e6. 2 indexed citations

Rakshit, Sagar, Radhika Bansal, Prashant Kapoor, et al.. (2021). Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood. 138(Supplement 1). 1630–1630.

Hwa, Yi L., Martha Q. Lacy, Morie A. Gertz, et al.. (2020). Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal Of Haematology. 106(3). 433–436. 2 indexed citations

Ravindran, Aishwarya, Kandace A. Lackore, Amy E. Glasgow, et al.. (2020). Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. Mayo Clinic Proceedings. 95(5). 944–954. 7 indexed citations

Hobbs, Miriam, Amie Fonder, & Yi L. Hwa. (2020). Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management. Journal of the Advanced Practitioner in Oncology. 11(4). 381–389. 3 indexed citations

10.

Sidiqi, M Hasib, Abdullah S. Al Saleh, Nelson Leung, et al.. (2019). PF625 VENETOCLAX FOR THE TREATMENT OF TRANSLOCATION (11; 14) AL AMYLOIDOSIS. HemaSphere. 3(S1). 265–266. 1 indexed citations

11.

Nandakumar, Bharat, Moritz Binder, Angela Dispenzieri, et al.. (2019). Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. Journal of Clinical Oncology. 37(15_suppl). 8039–8039. 33 indexed citations

12.

Dispenzieri, Angela, Michelle L. Mauermann, Betsy LaPlant, et al.. (2019). A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. Blood. 134(Supplement_1). 1846–1846. 3 indexed citations

13.

Sidana, Surbhi, Nidhi Tandon, Angela Dispenzieri, et al.. (2018). Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia. 33(3). 730–738. 16 indexed citations

14.

McCullough, Kristen, Miriam Hobbs, Jithma P. Abeykoon, & Prashant Kapoor. (2018). Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. Current Hematologic Malignancy Reports. 13(2). 114–124. 23 indexed citations

15.

Rajkumar, S. Vincent, Francis K. Buadi, Morie A. Gertz, et al.. (2018). Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. Journal of Clinical Oncology. 36(15_suppl). 8030–8030. 2 indexed citations

16.

Tandon, Nidhi, Surbhi Sidana, Angela Dispenzieri, et al.. (2017). Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology. 93(1). 17–22. 6 indexed citations

17.

Hwa, Yi L., Rahma Warsame, Morie A. Gertz, et al.. (2017). Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis. Blood. 130(13). 1578–1584. 13 indexed citations

18.

Sidana, Surbhi, S. Vincent Rajkumar, Angela Dispenzieri, et al.. (2017). Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology. 92(7). 668–673. 67 indexed citations

19.

Abeykoon, Jithma P., Miriam Hobbs, Jonas Paludo, et al.. (2016). Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood. 128(22). 5576–5576. 1 indexed citations

20.

Tandon, Nidhi, S. Vincent Rajkumar, Martha Q. Lacy, et al.. (2016). Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. Journal of Clinical Oncology. 34(15_suppl). 8017–8017. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact